Primary renal sarcoma is a rare tumor that accounts for approximately 1% - 3% of malignant renal neoplasms, and leiomyosarcoma is the most common subtype, which accounts for 50% - 60% of all renal sarcomas (
3). Primary RSS, a mesenchymal tumor occurring mainly in adults, is an extremely rare neoplasm (
3,
4). It was described firstly by Argani et al. in 1999 and since then, approximately 120 cases of RSS have been reported in the literature (
2,
5,
6).
RSS can be initially misdiagnosed as renal cell carcinoma because of similar clinical characteristics (
7). In previous reports, age of RSS patients ranged from 17 to 78 years (median: 36.5 years), and no gender predominance was observed (
8,
9). Patients with RSS might be asymptomatic or suffer from abdominal pain, hematuria, fever, and dysuria (
10). All sorts of presenting clinical characteristics may arise based on location and size of the lesion.
CT and MRI imaging provided useful information for determining the extent and invasiveness of the lesion. Because renal cell carcinoma (RCC) is the most common neoplasm, which accounts for approximately 80% of renal neoplasms (
10), it is necessary to compare radiological characteristics of other tumors with that of RCC, for example clear cell RCC, the most common subtype. Although it is highly difficult to differentiate RSS from RCC based on clinical symptoms, some radiographic characteristics may be helpful for differential diagnosis.
In radiological literature, RSS has been described as large well-defined soft tissue masses with heterogeneous contrast enhancement (
3). Some neoplasms may be dominantly cystic accompanied by enhancing septa and mural nodules (
11). The solid component of the neoplasms revealed the ‘rapid wash-in and slow wash-out’ pattern of contrast enhancement on multiphase images, which is a distinctive feature in contrast to most common renal neoplasms (
11). The heterogeneous signal intensity on T2-weighted images is described as ‘triple sign’, which is represented by regions of low, intermediate, and high signal intensity (
3,
12). However, clear cell RCC has peak enhancement on corticomedullary phase image and its necroses or cystic areas are located in the center of the tumor (
11,
13). ADC value of clear cell RCC (1.81 × 10
-3 mm
2/s) is higher than that of non-clear cell RCC (
14).
In our case, CT and MRI demonstrated a heterogeneous soft tissue density or intensity mass, and after intravenous contrast injection, we found slightly heterogeneous and progressive enhancement with hemorrhage and cysts. ADC value of this case was lower than that of clear cell RCC. The contiguous anatomical structures were infiltrated suggesting a malignant lesion. Similar to previously reported cases, the present case also presented a solid-cystic lesion with the cyst located on the tumor margin and‘triple sign’ on T2-weighted images (
3,
11,
12). Unlike previous cases, our case showed slight progressive enhancement (
3,
11,
12).
Macroscopically, RSS is a large solid mass with areas of hemorrhage, necrosis, and cyst. The histological finding in these cases demonstrate tumors composed of round spindle cells. Neoplastic cells are monomorphic, hyperchromatic, and mitotical (
8). Synovial sarcomas can be divided into two subtypes, namely monophasic and biphasic, based on the absence or existence of well-developed glandular epithelium cells. In addition, the monophasic subtype is more frequent, but its prognosis is poorer (
15).
Immunohistochemical analysis showed diffuse expression of
BCL-2, which occurs in more than 98% of RSS cases. In addition, diffuse or focal immunoreactivity for CD99 is noted in about 60% of cases (
15). Some synovial sarcomas express
EMA as the only marker of epithelial differentiation. Synovial sarcomas are characterized by a specific, commonly reciprocal t (X;18) (p11.2; q11.2) translocation. Namely, the SS18 (formerly named
SYT) gene (at 18q11) fuses with SSX genes (
8,
15). In our case, FISH analysis showed no evidence of translocation involving SYT gene.
No definite medical therapy has been established for RSS due to its rarity. Radical nephrectomy was the first approach for patients to resolve symptoms and achieve local control of the disease (
9). The prognosis for synovial sarcomas remains poor. In principle, chemotherapy is recommended, which mostly includes use of anthracyclines (adriamycin or epirubicin) and ifosfamide (
9,
15).